Commerzbank Aktiengesellschaft FI Purchases 218,948 Shares of Amgen Inc. (NASDAQ:AMGN)

Commerzbank Aktiengesellschaft FI increased its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 372.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 277,772 shares of the medical research company's stock after buying an additional 218,948 shares during the quarter. Amgen makes up 1.7% of Commerzbank Aktiengesellschaft FI's holdings, making the stock its 20th biggest position. Commerzbank Aktiengesellschaft FI owned about 0.05% of Amgen worth $72,398,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. lifted its holdings in Amgen by 25.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock valued at $3,441,909,000 after purchasing an additional 2,672,975 shares during the last quarter. Van ECK Associates Corp increased its position in Amgen by 263.8% during the 4th quarter. Van ECK Associates Corp now owns 1,038,593 shares of the medical research company's stock worth $270,699,000 after buying an additional 753,147 shares during the period. Nordea Investment Management AB increased its position in Amgen by 40.7% during the 4th quarter. Nordea Investment Management AB now owns 2,338,665 shares of the medical research company's stock worth $609,526,000 after buying an additional 676,598 shares during the period. Janus Henderson Group PLC increased its position in Amgen by 11.7% during the 3rd quarter. Janus Henderson Group PLC now owns 5,143,330 shares of the medical research company's stock worth $1,657,183,000 after buying an additional 538,545 shares during the period. Finally, Proficio Capital Partners LLC increased its position in Amgen by 35,087.4% during the 4th quarter. Proficio Capital Partners LLC now owns 470,808 shares of the medical research company's stock worth $122,711,000 after buying an additional 469,470 shares during the period. Institutional investors and hedge funds own 76.50% of the company's stock.

Wall Street Analyst Weigh In

AMGN has been the topic of several recent research reports. Leerink Partners lowered their price objective on Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Citigroup reiterated a "neutral" rating on shares of Amgen in a research report on Wednesday, February 5th. Redburn Partners lowered their price objective on Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Jefferies Financial Group restated a "buy" rating and issued a $380.00 price target on shares of Amgen in a research report on Tuesday, November 12th. Finally, Truist Financial decreased their price target on Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a research report on Wednesday, January 8th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Amgen has a consensus rating of "Hold" and a consensus price target of $314.09.

Insider Buying and Selling at Amgen

In other news, EVP Jonathan P. Graham sold 25,045 shares of the business's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the sale, the executive vice president now owns 28,987 shares in the company, valued at $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the business's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares of the company's stock, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is currently owned by company insiders.

Amgen Trading Up 0.5 %

Shares of AMGN stock traded up $1.41 during mid-day trading on Tuesday, reaching $312.19. 3,819,193 shares of the stock traded hands, compared to its average volume of 2,546,395. The stock's fifty day simple moving average is $282.76 and its two-hundred day simple moving average is $299.66. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a market cap of $167.71 billion, a price-to-earnings ratio of 41.35, a price-to-earnings-growth ratio of 2.63 and a beta of 0.56. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be paid a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.05%. Amgen's dividend payout ratio (DPR) is presently 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.